Lilly Announces Positive Type 2 Diabetes Data

mia.burns Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly’s Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes Improvements ...

Agenus taps investors after upbeat PhII data for brain cancer vaccine

Ryan McBride Agenus has struck a deal to raise about $ 6.5 million from institutional backers in a direct offering of common stock and warrants. The financing was announced a day after ...

Visterra Shares Flu Data

mia.burns Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential Preclinical results presented at ...

Lipidor reports positive clinical Phase I/II data in psoriasis

barbara.lempert STOCKHOLM – August 27, 2013. Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO®/calcipotriol ...

Industry Voices: Researching ALS through new eyes–Why data science will foster life science breakthroughs

Alok Saboo An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure ...

Report: Amgen balks at $9.5B Onyx bid after data dispute

John Carroll Quoting sources, Bloomberg says that Amgen is now pushing for a lower price after Onyx refused to hand over data from an ongoing study of the blood-cancer drug Kyprolis ...

MannKind rewarded for positive Afrezza data with $40M financing

John Carroll MannKind's positive take on interim Phase III data for its inhaled insulin Afrezza has a big sweetener tied to it. The Valencia, CA-based MannKind has picked up a much-needed ...

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study

barbara.lempert Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC   —  Encouraging results from the first proof-of-concept ...

Questions on MannKind’s inhaled insulin PhIII data cloud Afrezza’s future

John Carroll Early yesterday MannKind's Phase III data for Afrezza looked like a big hit with investors. But after a second look at the trial results, analysts' enthusiasm–and ...

M&A watch: Amgen and Onyx haggle over Kyprolis data in stalled buyout talks

Ryan McBride As sources tell Bloomberg, the companies have been stalled in their talks over Amgen's proposed $ 130-per-share acquisition of Onyx because Amgen wants data from an ...

AIDS Group Wins Legal Battle With FDA Over Confidential Data

esilverman Over the past three years, the AIDS Healthcare Foundation waged a losing battle against Truvada, which is sold by Gilead Sciences, for AIDS prevention. The Los Angeles-based ...

Disgraced researcher blames GSK pressure for Chinese data lapses

Tracy Staton A feature in Bloomberg today highlights GSK's unusual decision to give its research division in China the lead role in neuroscience drug development. FiercePharma News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS